Disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
CASI - Key Highlights

• Launched first commercial product EVOMELA® in China – August 2019
• Over 100 employees led by global management team with deep knowledge of US and China global drug development, regulatory, tech transfer, & commercial
  • Continued expansion in commercial operations (70+ employees, 90% have prior commercial sales experience in hematology oncology products;
  • Senior commercial team, each with more than 10 years experiences at large international pharma
• Growing pipeline with focus in hematological malignancies
• Active BD to pursue further pipeline expansion
• State-of-the-art GMP manufacturing facility currently in design stage
• Strong cash position – year end at $53.6 million; US NASDAQ company backed by long-term fundamental investors
Recent Execution in Hematology Oncology Portfolio

<table>
<thead>
<tr>
<th>Month</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>August 2019</td>
<td>Launched <em>Evomela</em> (melphalan) for injection in China</td>
</tr>
<tr>
<td>June 2019</td>
<td>In-licensed exclusive global rights to commercialize CD19 CAR-T cell therapy</td>
</tr>
<tr>
<td>April 2019</td>
<td>In-licensed exclusive global rights to novel anti-CD38 monoclonal antibody program – targeting multiple myeloma</td>
</tr>
<tr>
<td>March 2019</td>
<td>Received China NMPA approval for registration trial</td>
</tr>
<tr>
<td>November 2019</td>
<td>In-licensed China rights to Octreotide for neuroendocrine tumors and acromegaly</td>
</tr>
</tbody>
</table>
EVOMELA® Launched in China for Multiple Myeloma

- Successfully launched in mid-August 2019 – $4.1 million revenue for the year ended December 31, 2019
- The only form of melphalan commercially available in China
- HDT + ASCT is 1st line treatment for multiple myeloma even in new agent era
- Provides best choice of preparative regimen
  - Lack of propylene glycol solvent (related to certain adverse events)
- Stable and significantly improves handling for physicians
  - Captisol formulation allows for increased stability when reconstituted for patient administration
- Post-marketing study in 2020
### Innovative Cell Therapy with Global Commercial Rights

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>IN-LICENSED</th>
<th>CHINA CTA FILING &amp; REVIEW</th>
<th>REGISTRATION TRIAL</th>
<th>NDA FILING &amp; REVIEW</th>
<th>LAUNCH IN CHINA</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNTC19 (Autologous Anti-CD19 T-cell therapy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-Cell Non-Hodgkin Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-Cell Acute Lymphoblastic Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Innovative Drug Candidate with Global Rights

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>PRE-CLINICAL</th>
<th>IND/IMPD FILING &amp; REVIEW</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>CID-103 (Anti-CD 38 mAb)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### U.S. FDA-Approved Products with Greater China Rights

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>IN-LICENSED</th>
<th>CTA FILING &amp; REVIEW</th>
<th>REGISTRATION TRIAL</th>
<th>NDA FILING &amp; REVIEW</th>
<th>LAUNCH IN CHINA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZEVALIN®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin’s Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Product with Greater China Rights

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>IN-LICENSED</th>
<th>CTA FILING &amp; REVIEW</th>
<th>REGISTRATION TRIAL</th>
<th>NDA FILING &amp; REVIEW</th>
<th>LAUNCH IN CHINA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Octreotide LAI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptoms associated with neuroendocrine cancers and acromegaly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CNCT-19: CD19 CAR-T Cell Therapy

- Targets CD19, a B-cell surface protein widely expressed during all phases of B-cell development and validated target for B-cell derived hematological malignancies
- CD19-targeted CAR have demonstrated consistently high antitumor efficacy in children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma (B-NHL)
- CD19 antigen is the most frequently used biomarker in CAR-T cell therapy clinical trials for hematological malignancies
- Exclusive China and global commercial rights
- Clinical trial application approved by NMPA December 2019 for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL);
  - Registration trial initiated and first patient dosed
- Clinical trial application approved by NMPA December 2019 for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL);
  - Registration trial expected to initiate in mid-2020
CID-103: Potential Best in Class Anti-CD38 mAb

- Fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope; engineered to have strong ADCC activity against CD38 malignant cells and to reduce CDC activity with a potential reduction of infusion reactions with observed with existing anti-CD38 treatments
- Encouraging preclinical efficacy & safety profile compared to other anti-CD38 mAbs
- Demonstrates greater ADCC activity over Daratumumab and other anti-CD38 mAbs
- In vivo activity outperforms Daratumumab and other anti-CD38 mAbs
- Survival improvement observed in Daudi, Ramos and Raji Xenograft models
- Exclusive global license and commercial rights
- CID-103 is at IND/IMPD submission stage of development; phase I study targeted for late 2020 or 1H2021
Other Assets

ZEVALIN®

• CD20-directed radiotherapeutic antibody indicated for treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (FNHL) and patients with previously untreated follicular non-Hodgkin’s Lymphoma (FNHL) and patients with previously untreated follicular non-Hodgkin’s Lymphoma
• ZEVALIN is approved and commercialized in the U.S.; CASI has exclusive greater China rights
• China registration study expected to be initiated in 2021

Octreotide Long Acting Injectable (LAI)

• Octreotide LAI formulations are considered a standard of care for the treatment of acromegaly and the control of symptoms associated with certain neuroendocrine tumors
• Octreotide LAI has recently been approved in various European countries; CASI has exclusive China rights for development and distribution
• China registration study expected to be initiated in 2020
Global Senior Management Team

Wei-Wu He, PhD
Chairman and CEO

Larry Zhang, President

Alex Zukiwski, MD, CMO

Thomas Zhang, China Commercial GM

Jim Goldschmidt, PhD, SVP, BD

Cissy Wang, COO (CASi China)

Cynthia Hu, JD, COO (US), General Counsel & Secretary
CASi Recap

• Launched EVOMELA® (melphalan for injection) for multiple myeloma, the only commercially available melphalan in China

• Robust pipeline in hematology oncology
  • CNCT-19 (CD19 CAR-T Cell Therapy), potential to be the first China-developed CD-19 CAR-T for B-NHL, B-ALL
  • CID-103 (potential best in class anti-CD38 mAb) for multiple myeloma
  • ZEVALIN® (ibritumomab tiuxetan injection) for non-Hodgkin’s lymphoma
  • Thiotepa novel formulation (chemotherapeutic agent for use prior to hematopoietic stem cell transplantation
  • Other pipeline assets include Octreotide (long acting injectable (LAI) for use in neuroendocrine cancer setting)

• Led by an international executive team, with strong commercial and clinical/regulatory teams trained at large pharma, 100+ employees

• State-of-the-art GMP manufacturing facility currently in design stage; completed acquisition of land use rights for approximated 17.6 acres of land

• Strategic Business Development approach has enabled opportunistic pipeline expansion

• Strong cash position – year end at $53.6 million; US NASDAQ company backed by long-term fundamental investors